219298-65-4

Basic information

• Product Name: 2-hydroxy-6-Methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde
• Synonyms: 2-hydroxy-6-Methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde
• CAS NO: 219298-65-4
• Molecular Formula: C13H16O4
• Molecular Weight: 236.268
• Mol File: 219298-65-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-hydroxy-6-Methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxy-6-Methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde(219298-65-4)
• EPA Substance Registry System: 2-hydroxy-6-Methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde(219298-65-4)

Safety Data

• Hazardous Substances Data: 219298-65-4(Hazardous Substances Data)

Upstream product

• 487-69-4 2,4-dihydroxy-6-methylbenzaldehyde 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 1265361-64-5 {6-[2-(2,5-dimethoxy-benzylamino)-pyrimidin-4-yloxy]-1-hydroxy-4-methyl-1, 3-dihydrobenzo[c][1,2]oxaborol-3-yl}-acetic acid 
• 1265361-62-3 {6-[2-(2,5-dimethoxy-benzylamino)-pyrimidin-4-yloxy]-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl}-acetic acid ethyl ester 
• 1265359-19-0 2-methyl-4-(tetrahydro-2H-pyran-2-yloxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 
• 1265356-56-6 {6-[3-(3-amino-propoxy)-phenoxy]-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl}-acetic acid 
• 1265361-12-3 {6-[3-(3-tert-butoxycarbonylamino-propoxy)-phenoxy]-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl}-acetic acid 
• 1265361-10-1 {6-[3-(3-tert-butoxycarbonylamino-propoxy)-phenoxy]-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl}-acetic acid ethyl ester 
• 1265361-08-7 [1-hydroxy-6-(3-hydroxy-phenoxy)-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl]-acetic acid ethyl ester 
• 1265361-06-5 [6-(3-benzyloxy-phenoxy)-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl]-acetic acid ethyl ester 
• 1265361-04-3 4-(3-benzyloxy-phenoxy)-2-methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzaldehyde 
• 1265361-02-1 tfluoromethanesulfonic acid 5-(3-benzyloxy-phenoxy)-2-formyl-3-methyl-phenyl ester 
• 1265361-00-9 4-(3-benzyloxy-phenoxy)-2-hydroxy-6-methyl-benzaldehyde 
• 1265360-98-2 4-(3-benzyloxy-phenoxy)-2-methoxymethoxy-6-methyl-benzaldehyde 
• 1265360-96-0 4-hydroxy-2-methoxymethoxy-6-methyl-benzaldehyde 
• 1265356-53-3 [6-(3-benzyloxy-phenoxy)-1-hydroxy-4-methyl-1,3-dihydro-benzo[c][1,2]oxaborol-3-yl]-acetic acid ethyl ester 

Relevant articles and documents

1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS

Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula:A typical example for a compound according to above formula is: A typical example for a compound according to above formula is:

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.